[Preprint] Estudo RECOVERY mostra que baricitinibe reduz mortes em pacientes internados com COVID-19.

Comunicado de imprensa: RECOVERY trial shows Baricitinib reduces deaths in patients hospitalised with COVID-19 – University of Oxford

Estudo original: Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis – medRxiv

Comentários:

Arthritis drug reduces mortality in severe COVID-19, huge clinical trial finds – Science

Covid-19: Anti-inflammatory treatment baricitinib reduces deaths in patients admitted to hospital, finds trial – The BMJ

Another life-saving Covid drug identified – BBC

Conteúdos relacionados:

WHO recommends two new drugs (Baricitinib and Sotrovimab) to treat COVID-19.

RCT: Baricitinib reduced mortality in hospitalized adults with COVID-19.

Randomized trial: Baricitinib plus remdesivir reduce recovery time in patients with COVID-19

Comentário do autor no Twitter (fio – clique para saber mais)

RECOVERY pre-print: Baricitinib

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis https://t.co/g0cNjaBzEL

— Martin Landray (@MartinLandray) March 3, 2022